Get the Stockscreener App
30.93
0.23%
-0.07
Xoma Royalty Corp stock is traded at $30.93, with a volume of 26,983.
It is down -0.23% in the last 24 hours and down -4.80% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
See More
Previous Close:
$31.00
Open:
$30.74
24h Volume:
26,983
Relative Volume:
0.51
Market Cap:
$383.01M
Revenue:
$9.71M
Net Income/Loss:
$-29.96M
P/E Ratio:
-8.8879
EPS:
-3.48
Net Cash Flow:
$-14.79M
1W Performance:
-4.21%
1M Performance:
-4.80%
6M Performance:
+23.72%
1Y Performance:
-2.55%
1-Day Range:
$30.31
$31.44
1-Week Range:
$29.07
$33.50
52-Week Range:
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
30.93 | 383.88M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | The Benchmark Company | Buy |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
Will XOMA Royalty Corporation (X0M1) stock test record highs in 20252025 Year in Review & Low Drawdown Momentum Ideas - Newser
Why XOMA Royalty Corporation (X0M1) stock appeals to dividend investorsEarnings Recap Report & Capital Efficient Trade Techniques - Newser
What earnings margins imply for XOMA Royalty Corporation(X0M) stockIPO Watch & Risk Managed Investment Strategies - Newser
Irish court approves XOMA Royalty’s acquisition of Mural Oncology By Investing.com - Investing.com India
Mural Oncology Announces Sanction of the Scheme by the High Court - The Manila Times
Mural Oncology plc Announces Court Approval of Scheme for Acquisition by XOMA Royalty Corporation's Subsidiary - Quiver Quantitative
Mural Oncology Announces Sanction of the Scheme by the High Court - Benzinga
Is XOMA Royalty Corporation (X0M1) stock a defensive play amid uncertaintyMarket Activity Summary & Weekly Watchlist for Consistent Profits - Newser
How robust is XOMA Royalty Corporation(X0M) stock financial position - Newser
XOMA Royalty (NASDAQ:XOMA) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Mural Oncology Shareholders To Receive $2.035 Cash Per Share In XOMA Royalty Acquisition - Nasdaq
XOMA Royalty to acquire Mural Oncology for $2.035 per share By Investing.com - Investing.com Nigeria
XOMA Royalty to acquire Mural Oncology for $2.035 per share - Investing.com India
Mural Oncology announces final cash consideration payable on acquisition close - TipRanks
Mural Oncology plc Announces Final Determination of Additional Price Per Share in Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty - The Manila Times
Mural Oncology (Nasdaq: MURA) to Be Acquired by XOMA Royalty for $2.035 Cash - Stock Titan
XOMA (NASDAQ:XOMAP) Trading 0.2% Higher – Should You Buy? - Defense World
Xoma completes $24.9M acquisition of cash-strapped Lava Therapeutics - The Business Journals
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - ADVFN
Xoma announces closing of transactions to acquire Lava Therapeutics - TipRanks
XOMA Royalty completes acquisition of LAVA Therapeutics - Investing.com
[8-K] XOMA Royalty Corp Reports Material Event - Stock Titan
XOMA Royalty completes acquisition of LAVA Therapeutics By Investing.com - Investing.com UK
XOMA Royalty Corporation Completes Acquisition of LAVA Therapeutics N.V. - Quiver Quantitative
XOMA Royalty (Nasdaq: XOMA) completes LAVA deal; investors get $1.04 plus CVR - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How XOMA Royalty Corporation (X0M1) stock reacts to Fed tighteningJobs Report & High Accuracy Trade Alerts - newser.com
How XOMA Royalty Corporation stock performs after earningsEarnings Recap Report & Long-Term Safe Investment Ideas - newser.com
How XOMA Royalty Corporation(X0M) stock behaves under inflation pressure2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
Is XOMA Royalty Corporation stock a safe buy before earningsRate Hike & Verified Momentum Stock Watchlist - newser.com
Is XOMA Royalty Corporation (X0M1) stock attractive for dividend growthNew Guidance & High Conviction Investment Ideas - newser.com
Can XOMA Royalty Corporation (X0M1) stock attract analyst upgrades2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
Why XOMA Royalty Corporation stock remains undervaluedJuly 2025 Setups & Technical Confirmation Trade Alerts - newser.com
How XOMA Royalty Corporation stock compares to market leadersTreasury Yields & AI Enhanced Market Trend Forecasts - newser.com
XOMA Royalty's (NASDAQ:XOMA) Earnings Aren't As Good As They Appear - Yahoo Finance
How strong is XOMA Royalty Corporation stock revenue growthEarnings Performance Report & Weekly High Return Stock Opportunities - newser.com
Why millennials buy XOMA Royalty Corporation (X0M1) stock2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Will XOMA Royalty Corporation stock keep outperforming rivals2025 Short Interest & Fast Gaining Stock Reports - newser.com
XOMAO | XOMA Royalty Corporation Depositary Stock Data, Price & News - Quiver Quantitative
XOMAO Stock Institutional Owners - Quiver Quantitative
LuxembourgXOMA Royalty Acquires LAVA Therapeutics - Mondaq
Xoma turns its attention to Repare | ApexOncoClinical Trials news and analysis - Oncology Pipeline
XOMAP | XOMA Royalty Corporation 8.625% Stock Data, Price & News - Quiver Quantitative
Q4 EPS Estimates for XOMA Royalty Cut by Leerink Partnrs - Defense World
Chart based analysis of XOMA Royalty Corporation trendsMarket Sentiment Report & Daily Growth Stock Tips - newser.com
Forecasting XOMA Royalty Corporation price range with options data2025 Breakouts & Breakdowns & Safe Entry Zone Identification - newser.com
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):